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Abstract 
Delivery of chemotherapy in the surgical bed has shown preclinical activity to control 
cancer progression upon subtotal resection of pediatric solid tumors, but whether this 
new treatment is safe for tumor-adjacent healthy tissues remains unknown. Here Wistar 
rats were used to study the anatomic and functional impact of electrospun nanofiber 
matrices eluting SN-38 –a potent chemotherapeutic agent- on several body sites where 
pediatric tumors such as neuroblastoma, Ewing sarcoma and rhabdomyosarcoma arise. 
We placed blank and SN-38-loaded matrices embracing the femoral neurovascular 
bundle or in direct contact with abdominal viscera (liver, kidney, urinary bladder, 
intestine and uterus). Foreign body tissue reaction to the implants was observed though 
no histologic damage in any tissue/organ. Skin healing was normal. Tissue reaction was 
similar for SN-38-loaded and blank matrices, with the exception of the hepatic capsule 
that was thicker for the former although within the limits consistent with mild foreign 
body reaction. Tissue and organ function was completely conserved after local 
treatments, as assessed by the rotarod test (forelimb function), hematologic tests (liver 
and renal function) and control of clinical signs. Overall, these findings support the 
clinical translation of SN-38 loaded nanofiber matrices to improve local control 
strategies of surgically resected tumors. 
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1. Introduction 
 
Surgery, radiation therapy (RT) and systemic chemotherapy are intensively combined as 
treatment plan for most pediatric solid tumors.[1] One of the goals of this treatment 
strategy is to minimize the risk of cancer recurrence in the primary location while 
minimizing systemic exposure and off-target toxicity such as secondary tumors and 
infertility upon systemic chemotherapy or RT, or functional sequelae due to aggressive 
surgery.[2] 
Children cancer survivors are a group of patients in which long-term and chronic 
adverse effects should be especially avoided [3]. Thus, the development of innovative 
treatments with better safety/activity profiles than the currently available is an urgent 
need. In line with this, Intra-Operative Electron Beam Radiation Therapy (IOERT) 
reached clinical practice in pediatric oncology to minimize the radiation of tissues 
surrounding a resected tumor.[4] IOERT is performed during the surgical procedure to 
apply controlled RT doses immediately after resection in the surgical bed that contains 
macroscopic or microscopic tumor rests.[5] However, IOERT requires expensive 
infrastructure and is not available in most health institutions around the world. In this 
scenario, other alternatives including Local Drug Delivery Systems (LDDS) are 
currently undergoing intensive preclinical investigation to address the unmet medical 
need of a safer and more efficacious local control of solid tumors by means of 
maximizing local drug distribution, while minimizing systemic exposure.[6]  
To pave the way to clinical trials, LDDS are made of biocompatible and FDA-approved 
polymers such as poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA) and 
poly(epsilon-caprolactone) (PCL) and may carry potent anticancer drugs that are not 
suitable for systemic administration due to their poor aqueous solubility and/or 
physicochemical instability.[6a, 6e] Recently we have studied PLA nanofiber matrices 
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loaded with microcrystals of the potent anticancer agent SN-38 (10-hydroxy-
camptothecin) to control the relapse of surgically removed pediatric tumors.[6e] SN-38, 
an inhibitor of topoisomerase I, is 1000 fold more active against malignancies than its 
prodrug irinotecan (camptothecin-11).[7] However, the clinical use of SN-38 is impeded 
by the extremely low solubility in water of its lactone form.[8] Thus, the improvement of 
SN-38 delivery to target tissues by means of chemical or formulation modifications has 
been the focus of several studies during recent years.[6a, 9] SN-38-loaded nanofiber 
matrices improve local control of extracranial pediatric solid tumors including 
neuroblastoma and Ewing sarcoma patient-derived xenografts, achieving minimal drug 
exposure in the circulating blood.[6e] The clinical application of these matrices would 
involve their insertion into the surgical bed to contact with unresectable tumor rests.[6e, 
10] Using microdialysis as sampling method in restrained animals we determined that 
SN-38 achieves high concentrations (up to 2.5 µM) in the virtual space surrounding the 
matrices.[6e] However, whether such high local exposure is toxic for non-tumoral tissues 
surrounding the drug-eluting matrix remains not fully characterized. This is especially 
important because pediatric tumor rests are usually adjacent, infiltrating or wrapping 
around vital organs including blood vessels, nerves and viscera, whose long-term 
function should be conserved.  
In this work we used an immunocompetent rat model to simulate the clinical conditions 
of pediatric patients undergoing tumor resection and we evaluated the local toxicity of 
local SN-38-loaded nanofiber matrices on the femoral neurovascular bundle and vital 
organs such as liver, kidney and bladder. Overall, our preclinical findings showed the 
high safety and tolerability of SN-38 loaded nanofiber matrices and reaffirm their 
potential as a drug delivery platform to control the relapse of surgically resected tumors. 
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2. Results 
2.1. Drug activity and in vitro characterization of the matrices 
We described previously the potent activity of SN-38 in a variety of human pediatric 
cancer cell lines, either as free drug or loaded in nanofiber matrices.[6e] In this study, we 
evaluated the cytotoxic activity of the drug in murine hepatocytes (H2.35) as a model of 
nontumor cells. We used Ewing sarcoma (SK-ES-1) and rhabdomyosarcoma (Rh30) 
cell lines as reference tumor models. First, we calculated the concentrations of free SN-
38 inhibiting 50% of cell proliferation (IC50). IC50 values (± 95% confidence intervals) 
for SK-ES-1 and Rh30 were 0.72 (0.64-0.81) and 2.8 (1.8-5.1) nM, respectively. 
Hepatocytes were more than 10-fold less sensitive to the antiproliferative effect of SN-
38, with an IC50 of 50 (30-114) nM (Figure 1A). The cytotoxic effect of SN-38 on cell 
monolayers, measured as the release of lactate dehydrogenase (LDH), was also more 
pronounced in tumor cells, compared to hepatocytes that were sensitive to SN-38 only 
at concentrations higher than 200 nM (Figure 1B). 
SN-38-loaded PLA/PLGA nanofiber matrices (local-SN-38) were produced by 
electrospinning, containing 18 µg SN-38/cm2, as previously described.[6e] Matrices 
without SN-38 (local-blank) were also manufactured. The matrices were 150 µm thick. 
SN-38-loaded matrices released completely the drug upon 24 h incubation in medium 
containing 2-hydroxypropyl-beta-cyclodextrin (HPBCD; 10% w/v) as solubilizer 
(Figure 1C). The drug remaining in the matrices was less than 0.1% at the end of the 
study. Thus, the release profile of SN-38 from the PLA/PLGA nanofiber matrices in 
vitro in solubilizing medium was comparable with the previously reported in PLA-only 
nanofibers.[6e] Then, the activity 0.25 cm2 matrices was evaluated in cell monolayers 
covering the surface (1.9 cm2) of culture wells. In this experiment we observed that the 
LDDS was potently active to inhibit pediatric cancer cells, while hepatocytes conserved 
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a significant fraction of their viability even after 48 h exposure to the LDDS (Figure 
1D). 
 
 
Figure 1. SN-38 activity and in vitro characterization of the matrices. A. 
Antiproliferative activity (MTS assay) of SN-38 against murine hepatocytes (H2.35), 
human Ewing sarcoma (SK-ES-1) and rhabdomyosarcoma (Rh30) cell lines. Values are 
expressed as % of MTS signal of control untreated cells that were considered 100%. 
Means and SD from 6 replicates at each SN-38 concentration are shown. B. Cytotoxic 
activity (LDH assay) of SN-38. LDH signal values from treated cells were corrected by 
subtracting the spontaneous LDH release by untreated control cells and are expressed 
as % of the maximum cytotoxic activity achieved in cells treated with lysis buffer. 
Means and SD from 6 replicates at each SN-38 concentration are shown. C. In vitro 
cumulative release of SN-38-loaded matrices in phosphate buffered saline containing 
10% HPBCD as solubilizer. Individual data from three replicates and the best-fitting 
curve using the Michaelis Menten model in Graphpad software are shown. D. Activity 
of SN-38 matrices (MTS assay) against cell culture monolayers upon exposures ranging 
8-48 h. Blank matrices did not show significant antiproliferative activity. 
 
2.2. Surgical models 
The main goal of our work was to simulate in a suitable animal model the clinical 
conditions in which pediatric cancer patients would receive LDDS matrices. To assess 
the local biocompatibility of the matrices in different target tissues and organs and their 
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function, three different experimental models were designed in Wistar rats (Figure 2). 
Matrices were cut in 2 cm2 (2 x 1 cm) rectangles for the application in the animals. 
2.2.1. Neurovascular model  
The aim of this model was to evaluate the effect of local-SN-38 matrices on the 
neurovascular bundles and skin scarring/healing. The right femoral neurovascular 
bundle of the rat was exposed and dissected in one centimeter length through a skin 
incision on the medial part of the right thigh. Then, the treatment was applied wrapping 
around the bundle.  
2.2.2. Hepatorenal model  
To study the toxicity of local-SN-38 on the liver and kidney surfaces, first left 
nephrectomy was performed by lumbotomy. Then, right lumbotomy was performed to 
expose the kidney and the lateral aspect of the liver. The treatment was applied and 
fastened to the upper and lateral surface of the kidney. 
2.2.3. Bladder model 
To address local urinary bladder, intestinal and uterine biocompatibility, lower median 
laparotomy was performed and the bladder, uterus and rectum were exposed. Then, the 
LDDS was applied on the posterior surface of the bladder, anterior and upper surface of 
the uterine corpus and anterior wall of the rectum, fastened with two sutures to the 
uterus and one to the rectum wall.  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
  
 
9 
 
 
Figure 2. Surgical procedure showing the preparation and dissection of the target 
structures, the placement of the 2 cm2 nanofiber matrices and their fastening with 
sutures (not visible in the bladder model due to fatty tissue interposition). Manufactured 
matrices were resistant to traction, flexible and adaptable to curved surfaces. Upon 
moistening with the body fluids of the rats they became more friable. Thus, sutures 
were carefully applied to avoid damaging the matrices during their fixation to the 
surfaces of the treated tissues.  
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A total of 18 animals were allocated to each experimental model and randomly assigned 
to one of the following treatment groups: (a) single insertion of 2 cm2 (2x1 cm) of a 
PLA/PLGA nanofiber matrix loaded with 36 µg of SN-38 (Local-SN-38 Group); (b) 
single insertion of 2 cm2 (2x1 cm) of a PLA/PLGA nanofiber matrix (Local-Blank 
Group); and (c) single surgery performed in the same conditions of the previous 
treatment groups, though without the administration of nanofiber matrices (Sham 
Group). To evaluate the short- (acute) and long-term (chronic) effect of the local 
treatment, we collected samples at two time points. Thus, half of the animals in each 
group were euthanized 16 days after the surgery (acute samples) and the remaining half 
was euthanized 70 days post-surgery (chronic samples). At both tissue sampling times 
the matrices appeared rigid and adhered to tissues in direct contact. 
 
2.3. Histopathology 
We did not observe any treatment-related histologic alterations in normal tissues 
including vessels, nerves and muscle (Figure 3), liver and kidney (Figure 4) or uterus, 
bladder and rectum (Figure 5). The nanofiber matrices could be identified as empty 
spaces in the formalin-fixed paraffin-embedded (FFPE) blocks, due to the solubilization 
of the polymer during the processing of the paraffin. They were identified in the 
neurovascular bundle (Figure 3), in contact with the renal and liver surfaces (Figure 4) 
or the bladder, uterine and rectal surfaces (Figure 5). 
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Figure 3. Histology of the Neurovascular model upon acute (16 day) or chronic (70 
days) exposure to local treatments. (M): matrix; (*): nerves; arrow heads: arteries; 
arrows: veins. Representative pictures are shown. Scale bars are 100 µm.  
 
 
Figure 4. Histology of the Hepatorenal model upon acute (16 day) or chronic (70 days) 
exposure to local treatments. (M): matrix; arrow heads: liver; arrows: kidney. 
Representative pictures are shown. Scale bars are 100 µm.  
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Figure 5. Histology of the Bladder model upon acute (16 day) or chronic (70 days) 
exposure to local treatments. (M): matrix; arrow heads: bladder wall (not visible in all 
samples due to farther disposition of the matrices in relation to bladder); arrows: uterus. 
Representative pictures are shown. Scale bars are 100 µm. 
 
The mean thickness of the matrices in the FFPE sections was 394 µm (range 192 - 958 
µm). Matrices appeared thicker in the Neurovascular group than in the Hepatorenal and 
Bladder groups (P = 0.013 at 16-day exposure and P = 0.001 at the 70-day exposure 
samples; ANOVA). This was likely due to the bending of the matrices during the 
surgical insertion to wrap around the narrow neurovascular bundles instead of an almost 
flat disposition on the surface of the other two models. 
Animals who received LDDSs presented chronic granulomatous inflammation with 
foreign body response, foreign body giant multinucleated cells and fibrous 
encapsulation of the matrices, independently of the location of the matrix (Figure 3, 4 
and 5). Conversely, in the Sham groups, we observed only chronic inflammatory 
infiltrate -including scattered multinucleated cells- related to the sutures but no changes 
in the remaining structures related with the surgical procedure. 
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All FFPE samples from animals receiving LDDSs presented a capsule quality score of 3 
(loose fibrous capsule) or 4 (thick and mature capsule). The capsule was less mature in 
the Hepatorenal and Bladder models as compared to the Neurovascular but differences 
were not statistically significant. The presence of SN-38 in the matrices did not modify 
the quality scores as compared to blank matrices. Mean (±SD) scores at day 16 were 3.8 
± 0.4 in Neurovascular, 3.2 ± 0.4 in Hepatorenal, and 3.3 ± 0.5 in Bladder. Scores did 
not increase significantly at day 70. We did not observe infiltration of lymphocytes or 
neutrophils, nor infection in any of the models.   
Mean capsule thickness was 242 µm (range 58-542 µm), and it was similar between 
SN-38-treated and Blank-treated groups in the Neurovascular and Bladder models 
(Figure 6A). Nevertheless, in the Hepatorenal model the mean capsule thickness around 
local-SN-38 matrices was significantly thicker than around local-blank ones in chronic 
treatment samples. Comparing models, we observed that the mean capsule thickness 
was higher in the Neurovascular model than in the Hepatorenal and Bladder ones, 
independently of the treatment assigned (Figure 6A). This could be due to the matrices 
wrapping around the neurovascular bundle. Also, the dissection of a non-existing space 
in the subcutaneous tissue to place the matrices might have led to higher inflammation 
than the placement on a solid organ without dissecting or damaging its surface.  
We counted a minimum of 4 and a maximum of 24 layers of fibroblasts surrounding the 
matrices. There were no differences in the number of fibroblast layers in the capsule 
among treatment groups in the Neurovascular and Bladder models. In the Hepatorenal 
model we found a higher number of fibroblast layers in the 16-day exposure samples of 
the Local-SN-38 group compared to the samples exposed to local-blank (Figure 6B).  
At the interface, we observed multiple layers of macrophages and leucocytes between 
the matrix and the capsule with no signs of infection in the samples. 
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Figure 6. Characterization of the fibrous capsules of the experimental models upon 
acute (16 days) and chronic (70 days) exposure to LDDS matrices. (A) Capsule 
thickness in µm (mean and SD of 3 animals). (B) Number of fibroblast layers in the 
capsules (mean and SD of 3 animals). *P = 0.0436 and ** P = 0.007, compared to 
samples exposed to local-blank matrices at the same time point (t test). 
 
2.4. Neurovascular function 
None of the animals in which the femoral neurovascular bundle was isolated and 
wrapped around with the matrices developed ambulation concerns such as limp, 
weakness or rigidity during all the experimental process. This is consistent with the 
histologic findings in which the artery, vein and nerve appeared normal after being in 
contact with the SN-38-eluting LDDS. The rotarod test helped assess this in an 
objective way. All the animals presented a positive rotarod test the day before the 
surgery and at the endpoint. Comparing the results at days 0, 3, 16 and the following 
weeks we observed no differences between treatment groups. Thus, animals conserved 
the motor function upon the exposure to local-SN-38 and local-blank treatments. 
 
2.5. Renal and hepatic function 
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We evaluated the renal and hepatic function by the analysis of serum creatinine and 
alanine aminostransferase (ALT) concentrations in the Hepatorenal and Bladder models 
at days 0, 16 and 70 (Table 1). Creatinine levels were in the 15.0-64.6 µmol L-1 range 
(median = 33.6 µmol L-1). Local-SN-38 matrices did not cause increase in serum 
creatinine concentrations in any case. We observed a progressive increase in creatinine 
serum concentrations in all the animals, which was more intense in unilateral 
nephrectomized rats that surpassed the reference intervals proposed by Boehm et al.,[11] 
probably as a consequence of single kidney resection and animal aging.  
 
Table 1. Blood biochemistry results (mean and SD of 3-6 animals) for renal (Creatinine, 
Cre) and hepatic (ALT) functions. 
Model Treatment 
Cre 
[µmol L-1] 
Day 0 
Cre 
[µmol L-1] 
Day 16 
Cre 
[µmol L-1] 
Day 70 
 ALT 
[IU L-1]a) 
Day 0 
ALT 
[IU L-1] 
Day 16 
ALT 
[IU L-1] 
Day 70 
H
E
P
A
T
O
R
E
N
A
L
 
Sham 
22.2  
(±1.4) 
43.7  
(±10.1) 
56.6  
(±0.8) 
 33.2  
(±5.3) 
43.2  
(±5.46) 
50  
(±6.2) 
Local-Blank 
21.7  
(±2.3) 
34.4  
(±1.9) 
59.3  
(±4.8) 
 27.8  
(±2.9) 
38.5  
(±8.7) 
35.7  
(±4.0) 
Local-SN-38 
22.7  
(±0.7) 
42.7  
(±10.0) 
59.6  
(±2.7) 
 32.7  
(±6.8) 
46.0  
(±3.8) 
36.3  
(±3.2) 
B
L
A
D
D
E
R
 
Sham 
29.4  
(±5.1) 
34.8  
(±10.2) 
46.2  
(±2.1) 
 61.3  
(±45.6) 
45.0  
(±14.1) 
48.3  
(±8.5) 
Local-Blank 
23.3  
(±3.1) 
39.9  
(±7.4) 
51.9  
(±0.8) 
 34.3  
(±6.9) 
42.7  
(±10.2) 
43.7  
(±1.5) 
Local-SN-38 
25.1  
(±5.1) 
38.4  
(±.8) 
50.0  
(±3.5) 
 33.8  
(±6.6) 
43.2  
(±13.1) 
41.3  
(±8.1) 
a)International units per liter 
 
ALT and aspartate aminotransferase (AST) are commonly used as screening for liver 
damage and their serum concentrations rise during hepatocellular injury;[12] ALT is the 
most specific biomarker of both.[13] ALT concentrations were in the 20-153 IU L-1 range 
(median = 38 IU L-1) and exposure to LDDSs did not alter the values. 
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Levels of total bilirubin, bilirubin fractions and gamma-glutamyl transpeptidase (GGT) 
serum concentrations were not detectable in most cases due to serum concentrations 
below the sensitivity of the methods used in clinical practice. Determinations of AST 
serum concentrations were dramatically interfered by the hemolysis produced during 
blood collection, so this parameter was not evaluable. 
 
2.6. Results on skin healing 
Five of eighteen animals of the Neurovascular biocompatibility model presented wound 
dehiscence the first 24 h after surgery because rats removed part of the surgical staples. 
Two of them belonged to the Sham group, two to the Local-Blank group and one to the 
Local-SN-38 group. No exposure of the nanofiber matrix was observed in any of these 
animals. Three animals required skin closure under anesthesia (one in each group). No 
further incidents in the skin healing process were observed during the follow up. The 
histologic study at endpoint did not reveal any scarring interference in any of the 
animals (Figure 7). 
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Figure 7. Histology of the skin wound at day 70 after matrix implantation or 16 days 
after sham surgery. (M): matrix; (MF): muscular fibers; (*): scarring tissue. 
Representative pictures are shown. Scale bars are 100 µm. 
 
2.7. Blood counts  
Hemoglobin (Hb), hematocrit (Hct), white blood cell count (WBC) and platelet count 
(PC) were assessed in the Hepatorenal and Bladder models at days 0, 16 and 70. Values 
were in the normal range and we did not find significant differences among treatments 
(Table 2). 
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Table 2. Blood count parameters (mean ± SD of 3-6 values). 
Model Treatment Hb 
[g dL-1] 
Day 0 
Hb 
[g dL-1] 
Day 16 
Hb 
[g dL-1] 
Day 70 
 Hct 
[%] 
Day 0 
Hct 
[%] 
Day 16 
Hct 
[%] 
Day 70 
 WBC 
[103 µL-1] 
Day 0 
WBC 
[103 µL-1] 
Day 16 
WBC 
[103 µL-1] 
Day 70 
 PC 
[105 µL-1] 
Day 0 
PC 
[105 µL-1] 
Day 16 
PC 
[105 µL-1] 
Day 70 
H
E
P
A
T
O
R
E
N
A
L
 Sham 
13.0 
(±0,5) 
14.1 
(±0.6) 
15.6 
(±0.3) 
 
36.2 
(±2.1) 
42.4 
(±4.2) 
49.9 
(±2.0) 
 
8.8 
(±2.6) 
8.9 
(±2.2) 
7.4 
(±.4) 
 
5.8 
(±7.6) 
9.0 
(±1.5) 
8.4 
(±0.1) 
Local-
Blank 
12.4 
(±0.9) 
13.7 
(±0.9) 
16.0 
(±0.3) 
 
33.5 
(±3.4) 
40.6 
(±5.6) 
50.3 
(±1.2) 
 
7.9 
(±2.1) 
8.8 
(±2.8) 
6.0 
(±2.4) 
 
5.9 
(±0.8) 
8.6 
(±1.5) 
8.6 
(±1.8) 
Local- 
SN-38 
13.0 
(±0.4) 
14.3 
(±1.1) 
15.5 
(±0.4) 
 
35.9 
(±1.4) 
41.8 
(±5.2) 
48.5 
(±0.8) 
 
9.1 
(±.8) 
8.4 
(±4.1) 
4.4 
(±0.3) 
 
6.4 
(±1.7) 
8.7 
(±0.6) 
8.1 
(±0.4) 
B
L
A
D
D
E
R
 
Sham 
14.2 
(±1.1) 
13.9 
(±0.6) 
15.1 
(±0.7) 
 
42.5 
(±5.8) 
39.9 
(±3.3) 
46.7 
(±3.8) 
 
8.5 
(±2.3) 
6.5 
(±2.8) 
3.3 
(2.3) 
 
9.0 
(±.2) 
9.0 
(±1.2) 
8.5 
(±1.3) 
Local-
Blank 
12.9 
(±0.7) 
14.5 
(±1.0) 
14.6 
(±0.2) 
 
35.6 
(±3.0) 
43.5 
(±5.0) 
44.2 
(±0.3) 
 
7.1 
(±2.3) 
7.8 
(±2.4) 
5.4 
(±3.0) 
 
6.1 
(±1.5) 
7.6 
(±1.1) 
8.4 
(±0.2) 
Local- 
SN-38 
12.6 
(±1.0) 
14.3 
(±0.6) 
15.4 
(±0.6) 
 
35.7 
(±3.5) 
42.1 
(±3.5) 
46.2 
(±1.3) 
 
8.1 
(±1.3) 
8.2 
(±2.0) 
7.0 
(±1.4) 
 
6.2 
(±0.7) 
7.2 
(±2.0) 
8.1 
(±0.8) 
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2.8. Weight and other clinical signs of systemic toxicity 
During the study the animals did not show signs of wellbeing loss, diarrhea, anorexia or other 
clinical signs. All animals gained weight at the end of the follow up regardless of the assigned 
group, and none of them presented weight loss greater than 10% at any time point 
(Supplemental Figure 1). 
 
3. Discussion 
After gross tumor resection, vital tissue structures such as vessels, nerves and solid viscera 
may contain macro- or microscopic tumor rests.[1a, 14] Peritumoral tissues remain exposed and 
sometimes partially damaged by the severity of the surgery, so it is important to determine 
whether the placement of any suitable anticancer LDDS in the surgical bed could lead to 
tissue-specific local toxicity. Our study provides the first comprehensive exploration of the 
compatibility of SN-38-loaded polymer nanofiber matrices in a model of healthy cells 
(murine hepatocytes) and in several tissues of the Wistar rat as a model of healthy tissues and 
organs. At the dosage studied (18 µg SN-38/cm2, for a total of 36 µg SN-38, corresponding to 
0.17 mg kg-1 for a mean rat weight of 215 g at treatment start), this LDDS was safe for the 
adjacent non-tumor tissue as demonstrated by several histology and functional analyses, and 
did not interfere with skin healing.  
We expected that FDA-approved PLA and PLGA polymers would cause foreign body 
reactions in the surrounding tissue, as previously described,[15] but we are the first to address 
the functional effect of such local reactions upon wrapping around a neurovascular bundle 
with SN-38-loaded PLA/PLGA nanofiber matrices. In the femoral neurovascular bundle, the 
femoral nerve innervates the quadriceps muscle -the major extensor muscle of the knee-[16] 
and the occlusion of the femoral artery can cause walking disturbance in rats during the first 2 
to 5 days after an injury.[17] Our functional study showed that malleable nanofiber matrices are 
suitable to embrace vital neurovascular structures without causing a functional damage even 
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upon eluting SN-38 at high localized concentrations. Similarly, our results demonstrate that 
vital organs such as liver, kidney, urinary bladder and other structures in abdominal or pelvic 
locations are not damaged by this delivery system. This biocompatibility property opens new 
clinical possibilities for the application of the LDDS in the chemotherapy of surgically 
resected solid tumors. For example, in the field of pediatric oncology, 8% of neuroblastomas 
are not suitable for gross total resection due to the involvement of vascular and nerve 
structures and 55% of surgery-eligible patients still have disease after resection.[18] In addition, 
one out of ten patients will suffer vascular injury of a major vessel during surgery, which 
leads to nephrectomy in 5-10% of them.[19] The embryonal subtype of rhabdomyosarcoma, a 
common soft tissue sarcoma in childhood, frequently appears in the genitourinary location in 
less than 10 year old patients.[20] In this pelvic location, complete resection surgery is 
challenging and novel LDDS might help avoid undesirable damage or loss of pelvic organs 
that jeopardize the quality of life of young patients.[21] Similarly, other frequent non-central 
nervous system pediatric solid tumors such as Ewing sarcomas and synovial sarcomas usually 
appear in the proximity of vessels and nerves as their most frequent locations are pelvis, axial 
skeleton and extremities; 17 % of patients with Ewing sarcoma will present local or combined 
(local and systemic) relapse after primary treatment.[22] These patients would also be adequate 
candidates to receive the LDDS upon a subtotal resection surgery involving such vital 
structures. In pediatric cancer it is critical to ensure that off-target toxicity is reversible 
because these patients are likely to be long-term survivors. It is estimated that upon receiving 
currently available treatments, two thirds of pediatric cancer survivors will present at least one 
undesirable late-effect related to the cancer therapy, and one third will have serious life-
threatening complications.[23]  
Because in a previous study we observed that the drug elutes from the nanofibers following a 
bimodal release rate in vivo and penetrates 2 mm in the surrounding solid tumor tissue,[6e] we 
expected that the matrices eluting SN-38 would produce higher inflammation than blank 
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matrices in the adjacent organs. Among the models studied, only in the Hepatorenal we 
observed that SN-38-loaded systems produced more local inflammation (measured as the 
thickness of the fibrous capsule) than the blank counterparts. This could be explained by the 
susceptibility of the liver to irinotecan toxicity,[24] and by our in vitro experiments in murine 
hepatocytes, although we did not find hepatocellular damage or liver function alterations in 
the rats exposed to local-SN-38. Our findings in blood counts, liver and kidney function were 
consistent with the absence of histologic damage of the tissues in contact with the matrices. 
Our study finished 70 days after the insertion of the matrices and thus we did not address the 
biodegradability of the LDDS. However, it is likely that the matrices would be eliminated in 
the long term in the organism because they are made of hydrolytically degradable 
polyesters[25]. PLA is a slow degradation polymer (> 1 year) while PLGA (75/25) is degraded 
in 4-5 months by hydrolysis[25]. Additionally, the observed foreign body reaction suggests that 
the system would be eliminated actively due to the release of degradation mediators such as 
reactive oxygen intermediates, lytic enzymes and acid from the macrophages and foreign 
body giant cells[15b]. 
Systemic adverse events upon the administration of irinotecan include diarrhea and 
myelosuppression.[26] Plasma exposure to irinotecan-derived SN-38 is considered the main 
responsible of diarrhea due to intestinal mucosal damage after its biliary excretion.[27] Acute 
systemic adverse effects are rarely observed in rats receiving single intravenous 
administrations of up to 68 mg kg-1 of irinotecan –which would expose the organism to very 
high plasma concentrations of SN-38-,[28] while in our current study local SN-38 dosages 
were around 400-fold lower, which would lead to very low SN-38 exposure in plasma upon 
drug absorption from the administration site. For instance, in a previous study we found very 
low and transient plasma SN-38 concentrations (1 ng mL-1) in mice after a single local 
administration of 1 cm2 of LDDS loaded with 18 µg SN-38 –equivalent to 0.7 mg kg-1 for 
mice weighing 25 g-.[6e] Overall, our results confirm that the low systemic exposure after 
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local-SN-38 administration does not interfere with bone marrow function. Nevertheless, since 
granulocyte colony stimulating factor is used in the clinic to prevent neutropenia, 
myelosupression is no longer a limiting factor for current regimens of camptothecins in the 
clinical practice.[29]  
 
4. Conclusion 
Our study demonstrates the feasibility to apply anticancer SN-38 loaded nanofiber matrices 
next to vital organs and tissues without any significant detrimental effect on the surrounding 
tissues, blood and vital organs, and paves the way for translating this modular delivery 
technology to the clinic. 
 
5. Experimental section 
Preparation and characterization of polymer nanofiber matrices loaded with SN-38 
microcrystals 
SN-38-loaded nanofiber matrices (local-SN-38) were produced by electrospinning a 1:1 
mixture of PLA (MW > 100 kg mol-1, Velox GmbH, Hamburg, Germany) and PLGA (MW 
95 kg mol-1; lactic:glycolic ratio 75:25, Corbion, Amsterdam, Netherlands) and simultaneous 
electrospraying of SN-38 microcrystals.[6e] Matrices without SN-38 (local-blank) were also 
manufactured though without the cospraying of the microcrystals. The matrices were kept at -
20 ºC until they were used. 
The release profile of SN-38 from the matrices was characterized in vitro in medium 
containing the solubilizer HPBCD (molecular weight of 1400 g mol-1; Sigma Aldrich, St. 
Louis, MO). SN-38 was quantified by HPLC, as previously described.[6e] 
Cell lines and cytotoxicity assays 
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Mouse hepatocytes (H2.35; ATCC, Manassas, VA) were cultured in DMEM high glucose 
medium supplemented with 10% fetal bovine serum, 50 units mL-1 penicillin and 50 mg mL-1 
streptomycin (Life Technologies, Grand Island, NY) at 37 ºC and 5% CO2.  
Cell lines of pediatric solid tumors (Ewing sarcoma SK-ES-1 and rhabdomyosarcoma Rh30) 
were obtained from the repository maintained at Hospital Sant Joan de Deu (Barcelona, 
Spain) and cultured as previously described.[6e] 
The antiproliferative activity of SN-38 was characterized with the MTS assay (Promega, 
Fitchburg, WI) and IC50 ± 95% confidence intervals were calculated as previously 
described.[6e] The cytotoxicity of SN-38 was assessed using the LDH cytotoxicity assay kit 
from Pierce (Rockford, IL). For the LDH assay, 3,000 cells (mouse hepatocytes or human 
Ewing sarcoma and rhabdomyosarcoma) were plated per well in 96-well plates and cultured 
until monolayers covered the surface of the well. Then, SN-38 was added to the plate at 
concentrations ranging 1-0.00000256 nM). At 72 h LDH release from the cells was assessed.  
The antiproliferative activity of SN-38-loaded matrices was evaluated with the MTS assay as 
previously described.[6e] Blank matrices (no SN-38 content) were used as controls. 
Animals and surgical implantation of matrices 
Fifty-four 9 week-old female Wistar rats were used (Janvier, Zentralinstitut für 
Versuchstierzucht, Hannover, Germany). Animals were housed under standard conditions 
with water and chow ad libitum. The protocol was approved by the Animal Ethics Committee 
of the Universidad de Barcelona (approval number 8625) in accordance with the local, 
national and European legislation. All the animals were supervised and weighed the day of the 
surgery and weekly thereafter and clinical signs including wellbeing loss, limp, weakness or 
rigidity of hind limb, diarrhea and anorexia were recorded. 
Treatments (2 x 1 cm matrices) were fastened to the target locations using one 4/0 PLGA 
suture. Special attention was paid on the wound during postoperative supervision. The suture 
clips were removed one week after the surgery. All the surgeries were performed under 
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general anesthesia with isoflurane and analgesia with subcutaneous buprenorphine was 
administrated during the first 48 h after surgery. The muscular layer was sutured when needed 
with 4/0 PLGA sutures (Novosyn, B. Braun Medical AS, Spain) and the skin was closed 
using suture clips (Michel Suture Clips 11 x 2 mm, FST, Germany). 
At the experimental endpoint blood samples were obtained under ketamine/xylacine general 
anesthesia through cardiac puncture. After that, we performed left ventricle catheterization 
and wide right atrium opening. The animals were then perfused with 60 mL of PBS followed 
by 60 mL of 4% formaline. The following tissues were collected for histologic evaluation: 
skin covering the treatment area, neurovascular bundle and portion of muscle in contact 
(Neurovascular model), right kidney and portion of liver in contact with the right kidney 
(Hepatorenal model) and bladder, a portion of uterus and rectum (Bladder model). 
Functional assessment of neurovascular harm 
To assess the function of the hind limb in the experimental Neurovascular model, the rotarod 
performance test (Accelerating Rota Rod for 4 Rats, Panlab, Barcelona, Spain) was performed 
the day before the surgery and at days 3, 16 and weekly until the animals were sacrificed. A 
positive performance test was considered if the animal remained on the rotating rod during 5 
min in 2 of maximum 3 opportunities at 10 rpm constant speed. All the animals were trained 
in the test 2 weeks before the surgery. 
Histology  
Samples were fixed in 4% formalin, dehydrated in sequential concentrations of ethanol and 
embedded in paraffin. Then, 2 µm sections were cut from the FFPE blocks with a rotary 
microtome (HM 340E, Thermo Scientific, USA) in coronal direction for Hepatorenal, in 
transversal direction for Neurovascular, and in sagittal direction for Bladder samples. Sections 
were stained with hematoxylin/eosin. Masson trichrome was used to stain collagen fibers. 
Samples were examined under light microscope by a blinded expert pathologist who assigned 
scores in 3 different fields following a histomorphometric scale [30], grading from 0 to 4 the 
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aspect of the capsule -4 corresponds to a thick and mature capsule, 3 to a loose fibrous 
capsule, 2 to a capsule with dense and granulation tissue containing inflammatory cells and 
fibroblasts, 1 to inflammatory tissue without signs of fibrous tissue-. The thickness of the 
capsule and matrices was measured in micrometers in 3 different fields in each sample. We 
also measured the capsule thickness by counting the number of fibroblast layers in 3 different 
areas. All the surrounding tissues were inspected looking for signs of histological damage. 
Blood sampling 
Blood tests were performed in the experimental Hepatorenal and Bladder models the day of 
the surgery and at day 16 and 70. By retro-orbital sinus puncture, 500 µL of blood was 
collected in a 1.5 mL Eppendorf tube with 100 µL of EDTA 0,5 M (Sigma-Aldrich, Tres 
Cantos, Spain) and three 75 µL heparinized hematocrit capillaries (Deltalab, Barcelona, 
Spain) were filled. The day of sacrifice blood collection was performed by cardiac puncture 
and placed in K2EDTA and Z Serum Sep Clot Activator tubes (Vacuette, Greiner bio-one, 
Kremsmünster, Austria). 
We evaluated blood counts including Hct, WBC, PC and Hb with a hematology analyzer 
(ADVIA 2120, Siemens Healthcare, Erlangen, Germany). Creatinine, ALT, GGT, AST and 
bilirubin serum concentrations were analyzed by molecular absorption spectrometry 
(ARCHITECT c8000, Abott, IL, USA). 
Statistics 
Statistical analyses were carried out using GraphPad Prism 5 software (La Jolla, CA). 
Histologic images were obtained from three different microscopic fields from each sample of 
each animal allocated in each subgroup. Capsule scores, capsule thickness, number of 
fibroblasts in the capsule, matrix thickness, serum biochemistry, blood counts and weight 
were presented as means ± SD. We applied the Student’s t test to compare data from two 
treatment conditions or two sampling times and the ANOVA test to compare data from the 
three models. To compare the performance of rats in the rotarod test (3-10 animals per group), 
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we performed Pearson’s Chi-square test. We considered the differences statistically 
significant if p value was < 0.05. 
Supporting Information 
Supporting Information is available from the Wiley Online Library or from the author. 
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ToC entry 
 
Tissue-specific toxicity of SN38-loaded nanofiber matrices –a new delivery system for 
localized treatment of cancer- was studied in a rat model resembling the clinical 
condition of pediatric cancer patients undergoing subtotal resection surgery. The product 
was safe and biocompatible in vital structures including blood vessels, nerves and viscera, 
opening new clinical opportunities for this patient population. 
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Supplemental Figure 1. Weight of the rats receiving each treatment (Sham, Local-Blank and 
Local-SN-38), represented from the day of the surgery (t = 0) and during a 10 week period. 
Means ± SD of 9-18 animals are shown. 
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